Literature DB >> 23269626

Suberoyl bishydroxamic acid-induced apoptosis in HeLa cells via ROS-independent, GSH-dependent manner.

Bo Ra You1, Woo Hyun Park.   

Abstract

Suberoyl bishydroxamic acid (SBHA) is a HDAC inhibitor that can regulate many biological functions including apoptosis and proliferation in various cancer cells. Here, we evaluated the effect of SBHA on the growth of HeLa cervical cancer cells in relation to apoptosis, reactive oxygen species (ROS) and glutathione (GSH) levels. Dose-dependent inhibition of cell growth was observed in HeLa cells with an IC50 of approximately 15 μM at 72 h. SBHA also induced apoptosis in HeLa cells, as evidenced by sub-G1 cells, annexin V-FITC staining cells, activations of caspase 3 and 8, and the loss of mitochondrial membrane potential (ΔΨm). In addition, all of the tested caspase inhibitors rescued some cells from SBHA-induced HeLa cell death. SBHA increased ROS levels including O2(•-) and induced GSH depletion in HeLa cells. Generally, caspase inhibitors did not affect ROS levels in SBHA-treated HeLa cells, but they significantly prevented GSH depletion in these cells. Furthermore, while the well-known antioxidants, N-acetyl cysteine and vitamin C, did not affect cell death, ROS level or GSH depletion in SBHA-treated HeLa cells, L-buthionine sulfoximine, a GSH synthesis inhibitor, enhanced cell death and GSH depletion in these cells. In conclusion, SBHA inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis, and the inhibition is independent of ROS level changes, but dependent on GSH level changes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269626     DOI: 10.1007/s11033-012-2459-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  33 in total

1.  Histone modification at the gene level.

Authors:  Darren J Burgess
Journal:  Nat Rev Cancer       Date:  2012-02-24       Impact factor: 60.716

2.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.

Authors:  B H Huang; M Laban; C H-W Leung; L Lee; C K Lee; M Salto-Tellez; G C Raju; S C Hooi
Journal:  Cell Death Differ       Date:  2005-04       Impact factor: 15.828

Review 3.  Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.

Authors:  A Ganesan; L Nolan; S J Crabb; G Packham
Journal:  Curr Cancer Drug Targets       Date:  2009-12       Impact factor: 3.428

4.  Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis.

Authors:  Bo Ra You; Woo Hyun Park
Journal:  Mol Cell Biochem       Date:  2010-07-22       Impact factor: 3.396

Review 5.  HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.

Authors:  Matthew J Sweet; Melanie R Shakespear; Nabilah A Kamal; David P Fairlie
Journal:  Immunol Cell Biol       Date:  2011-10-25       Impact factor: 5.126

6.  Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears.

Authors:  M Anton; M Horký; S Kuchtícková; B Vojtĕsek; O Bláha
Journal:  Ceska Gynekol       Date:  2004-01

7.  Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Authors:  Junko Suzuki; Yunn-Yi Chen; Gary K Scott; Sandy Devries; Koei Chin; Christopher C Benz; Frederic M Waldman; E Shelley Hwang
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

8.  Apoptosis in pyrogallol-treated Calu-6 cells is correlated with the changes of intracellular GSH levels rather than ROS levels.

Authors:  Yong Hwan Han; Sung Zoo Kim; Suhn Hee Kim; Woo Hyun Park
Journal:  Lung Cancer       Date:  2007-10-24       Impact factor: 5.705

9.  Caspase inhibitor decreases apoptosis in pyrogallol-treated lung cancer Calu-6 cells via the prevention of GSH depletion.

Authors:  Yong Hwan Han; Suhn Hee Kim; Sung Zoo Kim; Woo Hyun Park
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

Review 10.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401

View more
  7 in total

1.  Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.

Authors:  Ferdinando Chiaradonna; Iros Barozzi; Claudia Miccolo; Gabriele Bucci; Roberta Palorini; Lorenzo Fornasari; Oronza A Botrugno; Giancarlo Pruneri; Michele Masullo; Alfonso Passafaro; Viviana E Galimberti; Valeria R Fantin; Victoria M Richon; Salvatore Pece; Giuseppe Viale; Pier Paolo Di Fiore; Giulio Draetta; Pier Giuseppe Pelicci; Saverio Minucci; Susanna Chiocca
Journal:  Antioxid Redox Signal       Date:  2015-05-27       Impact factor: 8.401

2.  Reactive oxygen species, glutathione, and thioredoxin influence suberoyl bishydroxamic acid-induced apoptosis in A549 lung cancer cells.

Authors:  Bo Ra You; Suhn Hee Kim; Woo Hyun Park
Journal:  Tumour Biol       Date:  2014-12-24

3.  xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells.

Authors:  Peng Zhang; Wei Wang; Zhenhui Wei; L I Xu; Xuanning Yang; Yuanhong DU
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

4.  Zerumbone increases oxidative stress in a thiol-dependent ROS-independent manner to increase DNA damage and sensitize colorectal cancer cells to radiation.

Authors:  Amit Deorukhkar; Niharika Ahuja; Armando-Lopez Mercado; Parmeswaran Diagaradjane; Uma Raju; Nalini Patel; Pranshu Mohindra; Nga Diep; Sushovan Guha; Sunil Krishnan
Journal:  Cancer Med       Date:  2014-12-01       Impact factor: 4.452

5.  Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer.

Authors:  Yu-Guo Yuan; Qiu-Ling Peng; Sangiliyandi Gurunathan
Journal:  Int J Nanomedicine       Date:  2017-09-05

Review 6.  Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands.

Authors:  Xuejiao Li; Yahong Liu; Hongqi Tian
Journal:  Bioinorg Chem Appl       Date:  2018-10-01       Impact factor: 7.778

Review 7.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Authors:  Robert Jenke; Nina Reßing; Finn K Hansen; Achim Aigner; Thomas Büch
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.